Twist Bioscience Corp
For the period ended Sep 30, 2024. Filed Nov 18, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Nov 18, 2024
TWST$120.79+0.1%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| (In thousands except per share data) | September 30, 2024 | September 30, 2023 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $226,316 | $286,470 |
| Short-term investments | 50,083 | 49,943 |
| Accounts receivable, net | 34,903 | 44,064 |
| Inventories | 24,078 | 32,063 |
| Prepaid expenses and other current assets | 11,396 | 11,716 |
| Total current assets | $346,776 | $424,256 |
| Property and equipment, net | 102,520 | 131,830 |
| Operating lease right-of-use assets | 58,829 | 71,531 |
| Goodwill | 85,811 | 85,811 |
| Intangible assets, net | 14,478 | 54,483 |
| Restricted cash, non-current | 2,816 | 2,811 |
| Other non-current assets | 3,093 | 5,681 |
| Total assets | $614,323 | $776,403 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $1,630 | $14,052 |
| Accrued expenses | 15,104 | 10,754 |
| Accrued compensation | 33,650 | 25,818 |
| Current portion of operating lease liability | 14,805 | 14,896 |
| Other current liabilities | 5,817 | 7,803 |
| Total current liabilities | $71,006 | $73,323 |
| Operating lease liability, net of current portion | 70,221 | 79,173 |
| Other non-current liabilities | 407 | 475 |
| Total liabilities | $141,634 | $152,971 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ equity | ||
| Common stock, $0.00001 par value — 100,000 and 100,000 shares authorized at September 30, 2024 and 2023, respectively; 58,877 and 57,557 shares issued and outstanding at September 30, 2024 and 2023, respectively | $— | $— |
| Additional paid-in capital | 1,715,119 | 1,657,222 |
| Accumulated other comprehensive loss | (522) | (756) |
| Accumulated deficit | (1,241,908) | (1,033,034) |
| Total stockholders’ equity | $472,689 | $623,432 |
| Total liabilities and stockholders’ equity | $614,323 | $776,403 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.